These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25202075)

  • 1. Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
    Aderhold C; Umbreit C; Faber A; Birk R; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2014 Sep; 34(9):4929-37. PubMed ID: 25202075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
    Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Umbreit C; Aderhold C; Faber A; Sauter A; Hofheinz RD; Stern-Straeter J; Hoermann K; Schultz JD
    Oncol Rep; 2014 Aug; 32(2):668-76. PubMed ID: 24890748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Umbreit C; Aderhold C; Faber A; Sommer JU; Sauter A; Hofheinz RD; Stern-Sträter J; Hoermann K; Schultz JD
    Anticancer Res; 2013 Jun; 33(6):2457-65. PubMed ID: 23749896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of MMP-2 and -14 expression by imatinib in HPV-positive and -negative squamous cell carcinoma.
    Faber A; Sauter A; Hoedt S; Hoermann K; Erben P; Hofheinz RD; Sommer U; Stern-Straeter J; Schultz DJ
    Oncol Rep; 2012 Jul; 28(1):172-8. PubMed ID: 22576800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Schultz JD; Sommer JU; Hoedt S; Erben P; Hofheinz RD; Faber A; Thorn C; Hörmann K; Sauter A
    Oncol Rep; 2012 Jan; 27(1):270-80. PubMed ID: 21993766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro.
    Aderhold C; Faber A; Grobschmidt GM; Chakraborty A; Bockmayer A; Umbreit C; Birk R; Stern-Straeter J; Hörmann K; Schultz JD
    Anticancer Res; 2013 Dec; 33(12):5385-93. PubMed ID: 24324073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
    Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
    Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
    Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecules alter VEGFR and PTEN expression in HPV-positive and -negative SCC: new hope for targeted-therapy.
    Aderhold C; Faber A; Umbreit C; Chakraborty A; Bockmayer A; Birk R; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2015 Mar; 35(3):1389-99. PubMed ID: 25750290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
    Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial Effects of Curcumin with an Anti-Neoplastic Agent on Head and Neck Squamous Cell Carcinoma Through the Regulation of EGFR-ERK1/2 and Apoptotic Signaling Pathways.
    Sivanantham B; Sethuraman S; Krishnan UM
    ACS Comb Sci; 2016 Jan; 18(1):22-35. PubMed ID: 26505786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
    Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
    Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma.
    Kramer B; Schultz JD; Hock C; Sauter A; Stuck BA; Hörmann K; Birk R; Aderhold C
    Oncol Lett; 2017 May; 13(5):3269-3276. PubMed ID: 28521433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma.
    Imanishi Y; Fujii M; Tokumaru Y; Tomita T; Kanke M; Kanzaki J; Kameyama K; Otani Y; Sato H
    Hum Pathol; 2000 Aug; 31(8):895-904. PubMed ID: 10987249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck.
    Franchi A; Santucci M; Masini E; Sardi I; Paglierani M; Gallo O
    Cancer; 2002 Nov; 95(9):1902-10. PubMed ID: 12404284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
    Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
    Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor-induced pyruvate dehydrogenase kinase 1 expression enhances head and neck squamous cell carcinoma metastasis
    Hsu JY; Chang JY; Chang KY; Chang WC; Chen BK
    FASEB J; 2017 Oct; 31(10):4265-4276. PubMed ID: 28596235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC.
    Schultz JD; Rotunno S; Erben P; Sommer JU; Anders C; Stern-Straeter J; Hofheinz RD; Hörmann K; Sauter A
    Oncol Rep; 2011 Apr; 25(4):1145-51. PubMed ID: 21249321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.